SciSparc and Clearmind's Groundbreaking Partnership
TEL AVIV, Israel — SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company specializing in treatments for central nervous system disorders, has announced an exciting collaboration with Clearmind Medicine Inc. (NASDAQ: CMND). This partnership has resulted in the filing of an international patent application aimed at developing a proprietary treatment for anorexia, bulimia, and other eating disorders.
Understanding the Treatment Approach
The patent application focuses on the unique combination of 3-Methylmethcathinone (3-MMC) and SciSparc’s Palmitoylethanolamide (PEA). This combination is designed to tackle the intricate neurobiological and psychological challenges associated with eating disorders, aiming to provide innovative pathways for effective treatment solutions.
The Impact of Eating Disorders
Eating disorders are serious health issues that can dramatically alter an individual's well-being, emotions, and overall functionality. These conditions are one of the leading causes of disability, particularly among young women, contributing to one of the highest mortality rates compared to other mental health issues. Presently, it is estimated that around 70 million people globally suffer from various eating disorders, with alarming growth rates, particularly among children and adolescents, indicating a shift in prevalence from 3.4% to 7.8% between the years 2000 and 2018.
About SciSparc Ltd.
SciSparc is driven by a dedicated team of experienced executives and scientists with a focus on the advancement of cannabinoid pharmaceuticals. The company is involved in multiple drug development programs utilizing THC and non-psychoactive CBD, including SCI-110 for treating Tourette Syndrome and agitation associated with Alzheimer's disease, and SCI-210, which is aimed at addressing issues such as Autism Spectrum Disorder (ASD) and status epilepticus. Moreover, SciSparc holds a significant stake in a subsidiary that markets hemp seed oil products through platforms like Amazon Marketplace.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage biotech specializing in psychedelic pharmaceuticals. The company is on a mission to discover and develop innovative treatments derived from psychedelics to address prevalent and underserved health issues, such as alcohol use disorder. Their portfolio boasts nineteen patent families, with 31 patents granted, and they actively seek to expand this through additional patents and by acquiring new intellectual property.
Future Outlook
As both companies progress with their research and development efforts, the outcomes from this collaboration hold significant promise for creating effective treatment options for eating disorders. With ongoing advancements, the potential to revolutionize how these mental health conditions are treated looms closer than ever.
Investor Contact Information
For further inquiries or information about SciSparc and its groundbreaking work, interested parties can reach out via email at IR@scisparc.com or by phone at +972-3-6167055.
Frequently Asked Questions
What is the main objective of SciSparc's partnership with Clearmind?
The partnership aims to develop innovative treatment options for anorexia, bulimia, and other eating disorders through a unique combination of compounds.
What are the potential benefits of the new treatment being developed?
The treatment addresses the neurobiological and psychological aspects of eating disorders, potentially improving outcomes for affected individuals.
How prevalent are eating disorders globally?
Approximately 70 million people are affected worldwide, with increasing rates among children and adolescents.
What does SciSparc specialize in?
SciSparc focuses on developing cannabinoid pharmaceuticals for various neurological disorders.
How can investors learn more about SciSparc?
Investors can contact SciSparc directly via email at IR@scisparc.com or call their contact number for inquiries.
